Research ExplorerPublicationsPhase I/II study on cytarabine and idarubicin combined with ...

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

Standard

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). / Krauter, Jürgen; Fiedler, Walter; Schlenk, Richard F; Paschka, Peter; Thol, Felicitas; Lübbert, Michael; Wattad, Mohammed; Verbeek, Mareike; Könecke, Christian; Neuhaus, Barbara; Papkalla, Armin; Kebenko, Maxim; Janning, Melanie; Döhner, Konstanze; Gaidzik, Verena I; Becker, Heiko; Greil, Christine; Reimer, Peter; Götze, Katharina S; Döhner, Hartmut; Ganser, Arnold; Heuser, Michael.

In: BRIT J HAEMATOL, Vol. 183, No. 2, 18.10.2018, p. 235-241.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Krauter, J, Fiedler, W, Schlenk, RF, Paschka, P, Thol, F, Lübbert, M, Wattad, M, Verbeek, M, Könecke, C, Neuhaus, B, Papkalla, A, Kebenko, M, Janning, M, Döhner, K, Gaidzik, VI, Becker, H, Greil, C, Reimer, P, Götze, KS, Döhner, H, Ganser, A & Heuser, M 2018, 'Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)', BRIT J HAEMATOL, vol. 183, no. 2, pp. 235-241. https://doi.org/10.1111/bjh.15546

APA

Krauter, J., Fiedler, W., Schlenk, R. F., Paschka, P., Thol, F., Lübbert, M., Wattad, M., Verbeek, M., Könecke, C., Neuhaus, B., Papkalla, A., Kebenko, M., Janning, M., Döhner, K., Gaidzik, V. I., Becker, H., Greil, C., Reimer, P., Götze, K. S., ... Heuser, M. (2018). Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). BRIT J HAEMATOL, 183(2), 235-241. https://doi.org/10.1111/bjh.15546

Vancouver

Krauter J, Fiedler W, Schlenk RF, Paschka P, Thol F, Lübbert M et al. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). BRIT J HAEMATOL. 2018 Oct 18;183(2):235-241. https://doi.org/10.1111/bjh.15546

Bibtex

@article{a55021ddda05445fbf045ce6dfbb9068,
title = "Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)",
abstract = "This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3-4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.",
keywords = "Journal Article",
author = "J{\"u}rgen Krauter and Walter Fiedler and Schlenk, {Richard F} and Peter Paschka and Felicitas Thol and Michael L{\"u}bbert and Mohammed Wattad and Mareike Verbeek and Christian K{\"o}necke and Barbara Neuhaus and Armin Papkalla and Maxim Kebenko and Melanie Janning and Konstanze D{\"o}hner and Gaidzik, {Verena I} and Heiko Becker and Christine Greil and Peter Reimer and G{\"o}tze, {Katharina S} and Hartmut D{\"o}hner and Arnold Ganser and Michael Heuser",
note = "{\textcopyright} 2018 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2018",
month = oct,
day = "18",
doi = "10.1111/bjh.15546",
language = "English",
volume = "183",
pages = "235--241",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

AU - Krauter, Jürgen

AU - Fiedler, Walter

AU - Schlenk, Richard F

AU - Paschka, Peter

AU - Thol, Felicitas

AU - Lübbert, Michael

AU - Wattad, Mohammed

AU - Verbeek, Mareike

AU - Könecke, Christian

AU - Neuhaus, Barbara

AU - Papkalla, Armin

AU - Kebenko, Maxim

AU - Janning, Melanie

AU - Döhner, Konstanze

AU - Gaidzik, Verena I

AU - Becker, Heiko

AU - Greil, Christine

AU - Reimer, Peter

AU - Götze, Katharina S

AU - Döhner, Hartmut

AU - Ganser, Arnold

AU - Heuser, Michael

N1 - © 2018 British Society for Haematology and John Wiley & Sons Ltd.

PY - 2018/10/18

Y1 - 2018/10/18

N2 - This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3-4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.

AB - This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3-4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.

KW - Journal Article

U2 - 10.1111/bjh.15546

DO - 10.1111/bjh.15546

M3 - SCORING: Journal article

C2 - 30378121

VL - 183

SP - 235

EP - 241

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 2

ER -